Andrew Blight, Chief Scientific Officer at ACORDA THERAPEUTICS INC (ACOR), sold 500 shares at $37.47 ($19K) on 2015-11-20, disclosed to the SEC on 2015-11-23.
Scheduled sale ($19k) by Chief Scientific Officer under a pre-arranged 10b5-1 plan. Pre-set trade — not a discretionary signal on the stock.
Negative factors outweigh the positive ones.
| Filing → |
| ACOR | SELL | 2015-10-21 | $1.0M | — | Filing → |
| ACOR | SELL | 2015-09-23 | $410K | — | Filing → |
| ACOR | SELL | 2014-10-22 | $1.7M | — | Filing → |